How do I buy Incyte (INCY) stock?

Buying Incyte (INCY) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "INCY", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy INCY by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if INCY is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Incyte (INCY) Stock

Q: What is the minimum investment for INCY on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Incyte from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · INCY

Trade INCY

Key stats

Market cap: $24.05B
Price / Earnings ratio: 62.1x
EPS (TTM): $2.09
Volume: Loading
52-week high: $132.60
52-week low: $89.25
EPS vs analyst estimate: +47.7%Q3 FY25 · $2.26 vs $1.53

Source: third-party data provider, as of November 7, 2026

EPS estimate: analyst consensus

Compare with INCY

Technical indicators

RSI 14: 50.83
MACD 12/26/9: 0.35
EMA 9 of MACD: -0.54
MACD histogram: 0.89
SMA 50: $119.78; Price below SMA 50
EMA 50: $118.02; Price below EMA 50
SMA 200: $108.36; Price above SMA 200
EMA 200: $110.09; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 14 analyst ratings

Strong Sell0

Sell0

Hold6

Buy8

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

6B4B2B0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

8B6B3B0

Revenue to Profit

2025

$5.1B

Revenue

$0.0

Cost of revenue

$4.8B

Gross profit

$0.0

Operating expenses

$1.3B

Net income

Earnings

EPS forecast

Actual EPS

$2.26

$1.53

Q3FY25

$1.81

Q4FY25

$1.55

Q1FY26

$1.61

Q2FY26

$1.65

Q3FY26

The market is expecting earnings per share of $1.65 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Incyte

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.Our unique expertise in medicinal chemistry and biology have enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists.

SectorHealthcare

IndustryBiotechnology

Employees2,844

CEOMr. William J. Meury

IPO DateNov 4, 1993

HeadquartersWilmington, DE

Key Executives

Name	Title	Year Born
Mr. William J. Meury	CEO & Director	1968
Mr. Suketu P. Upadhyay	Executive VP & CFO	1969
Dr. Pablo J. Cagnoni M.D., Ph.D.	President and Global Head of R&D	1963
Mr. Thomas Tray	Principal Financial Officer, VP of Finance & Chief Accounting Officer	1978
Dr. Steven H. Stein M.D.	Executive VP, Head of Late-stage Development & Chief Medical Officer	1967
Mr. Mohamed Khairie Issa	Executive Vice President & Head of U.S. Commercial	1983
Mr. Michael James Morrissey	Executive VP & Head of Global Technical Operations	1964
Ms. Alexis Smith	VP & Head of Investor Relations	—
Mr. Richard A. Hoffman J.D., M.B.A.	Executive VP, General Counsel & Secretary	1962
Ms. Pamela M. Murphy	VP of Investor Relations & Corporate Communications	1951

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											+1.8	+13.0
2022	+0.5	-9.2	+15.6	-6.2	-0.2	+1.3	+0.0	-9.0	-6.6	+8.0	+3.5	-0.4
2023	+7.0	-10.1	-7.1	+2.4	-18.3	+1.2	+2.6	+1.3	-10.7	-7.1	-0.1	+16.2
2024	-10.2	-1.4	-3.5	-8.1	+9.2	+3.1	+6.9	+1.9	-0.3	+8.9	-2.0	-5.7
2025	+6.7	-0.3	-13.8	+2.9	+4.9	+4.3	+9.0	+11.9	-1.4	+7.8	+2.8	-3.2
2026	-1.3	-1.4	-5.9	+1.0	-0.2	+18.6	+5.0	+4.0	-2.9	+2.8	+2.3

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

Agios Pharmaceuticals, Inc.

FAQ

Buying Incyte (INCY) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "INCY", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy INCY by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Incyte from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Incyte (INCY) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track INCY's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Incyte (INCY) Stock

Key stats

Compare with INCY

Recent news

Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.

Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

What Incyte (INCY) Said on Its Q3 Earnings Call

What Incyte (INCY) Said on Its Q3 Earnings Call

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.

Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

What Incyte (INCY) Said on Its Q3 Earnings Call

What Incyte (INCY) Said on Its Q3 Earnings Call

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers

Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

About Incyte

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade